A “systems medicine” approach to the study of non-alcoholic fatty liver disease  by Petta, Salvatore et al.
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a  b  s  t  r  a  c  t
The  prevalence  of  fatty  liver  (steatosis)  in  the  general  population  is  rapidly  increasing  worldwide.  The
progress  of  knowledge  in  the physiopathology  of fatty  liver  is  based  on  the  systems  biology  approach
to  studying  the  complex  interactions  among  different  physiological  systems.  Similarly,  translational  and
clinical research  should  address  the  complex  interplay  between  these  systems  impacting  on  fatty  liver.
The clinical  needs  drive  the  applications  of systems  medicine  to re-deﬁne  clinical  phenotypes,  assessing
the  multiple  nature  of  disease  susceptibility  and  progression  (e.g. the  deﬁnition  of risk,  prognosis,  diag-
nosis  criteria,  and  new  endpoints  of  clinical  trials).  Based  on  this  premise  and  in  light  of recent  ﬁndings,AFLD
ASH
ersonalized
ystems medicine
the  complex  mechanisms  involved  in  the pathology  of  fatty  liver  and  their  impact  on  the short-  and  long-
term  clinical  outcomes  of cardiovascular,  metabolic  liver  diseases  associated  with  steatosis  are  presented
in this  review  using  a  new  “systems  medicine”  approach.  A  new  data  set is proposed  for  studying  the
impairments  of  different  physiological  systems  that  have  an  impact  on  fatty  liver in  different  subsets  of
subjects  and patients.
 Gast©  2015  Editrice
. Introduction
The prevalence of non-alcoholic fatty liver disease (NAFLD) in
he general population is growing worldwide: 44% in the USA, 33%
n Europe and 25% in Italy [1–6]; for non-alcoholic steatohepati-
is (NASH), the progressive form of NAFLD, the estimate is 2–3%
3,5]. A large cohort study reported that NAFLD was associated with
6% higher 5-year overall health-care costs, mainly from cardio-
etabolic diseases [6].
Progress in the knowledge of NAFLD/NASH pathophysio-
ogy was driven by the “systems biology” approach, i.e. the
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el.: +39 050 543858; fax: +39 050 995457.
E-mail address: ferruccio.bonino@unipi.it (F. Bonino).
1See Appendix A.
ttp://dx.doi.org/10.1016/j.dld.2015.10.027
590-8658/© 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Allroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.
interdisciplinary study of complex interactions within different
biological systems. “Systems pathophysiology” studies the com-
plex interactions between major human vital systems and their
interplay. “Systems medicine” combines systems biology and
pathophysiological approaches to translational research, integrat-
ing various bio-medical tools and using the power of computational
and mathematical modelling. This enables the personalization
of diagnosis, prognosis and treatment. Systems medicine helps
to re-deﬁne clinical phenotypes using molecular and dynamic
parameters to discover new diagnostic and prognostic biomark-
ers and to guide the design of new clinical trials. Thus, a systems
medicine approach appears mandatory for a “patient-based” clas-
siﬁcation of the complex interactions between different biological
systems and physiological functions involved in NAFLD/NASH, now
grouped under the general deﬁnition of “metabolic syndrome”
(MetS; Table 1). A special interest group (SIG) of the Italian Asso-
ciation for the Study of the Liver (AISF) assembled after the 2013
Single Topic Conference on Personalized Hepatology, held in Pisa
 rights reserved.
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Table 1
(a) Deﬁnition of the metabolic syndrome, according to recent classiﬁcations. (b) Quantitative score to estimate the impact of metabolic factors on nonalcoholic fatty liver
disease.
(a)
Feature National Cholesterol Education Program,
ATP-III
International Diabetes Federation Joint statement of IDF, NHLBI, AHA, WHF, IAS,
IASO
Visceral obesity >102 cm (males), >88 cm (females) ≥94 cm (males), ≥80 cm (females)(ethnic
differences)
≥94 cm (males), ≥80 cm (females)(ethnic
differences)
Lipid levels TG ≥ 150 mg/dL or treated for dyslipidemia TG ≥ 150 mg/dL or treated for dyslipidemia TG ≥ 150 mg/dL or treated for dyslipidemia
HDL-Chol <40 mg/dL (males); <50 mg/dL
(females)
HDL-Chol <40 mg/dL (males); <50 mg/dL
(females)
HDL-Chol <40 mg/dL (males); <50 mg/dL
(females)
Arterial pressure ≥130/85 mmHg  or treated for Htx ≥130/85 mmHg  or treated for Htx ≥130/85 mmHg or treated for Htx
Blood glucose ≥110 mg/dL or treated for DM ≥100 mg/dL or treated for DM ≥100 mg/dL or treated for DM
Notes 3 of the above Visceral obesity + 2 of the above 3 of the above
Grade
(b)
0 No abdominal adiposity and no other features of MetS
1 Abdominal adiposity
2  Abdominal adiposity + 1 feature of MetS (i.e. atherogenic dyslipidemia, low HDL cholesterol and/or high TG, hypertension or fasting hyperglycemia/glucose
intolerance/diabetes)
3  Abdominal adiposity + 2 features of MetS
4  Abdominal adiposity + 3 features of MetS
Abbreviations:  ATPIII, Adult Treatment Panel-III; IDF, International Diabetes Federation; NHBLI, National Heart, Blood and Lung Institute; AHA, American Heart Association;
WHF, World Heart Federation; IAS, International Atherosclerosis Society; IASO, International Association for the Study of Obesity; DM,  diabetes mellitus; TG, triglycerides;
Htx,  hypertension; HDL, High Density Lipoprotein; MetS, Metabolic Syndrome.
Notes:
The 10-year risk of having a cardiovascular disease (CVD) can be estimated by the Framingham risk score equation inserting major CVD risk factors (i.e., age, sex, total
cholesterol, HDL-cholesterol, smoking history, systolic blood pressure and current use of anti-hypertensive drugs) of the individual patient in the NIH web site: http://
cvdrisk.nhlbi.nih.gov/.
All patients included in either score 0 or score 1 are in primary prevention of CVD.
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araditional CVD risk factors considered are as follows: family history of premature 
r  on treatment), LDL-C ≥130 mg/dl (or on treatment), atherogenic dyslipidemia (i
reatment), obesity (BMI ≥30 kg/m2) and CKD (estimated glomerular ﬁltration rate
n October 2013. The steering and writing committees of this
ork included all the experts of the NAFLD/NASH session. Using a
igorous, evidence-based approach, the experts identiﬁed and syn-
hesized the literature that forms the evidence regarding speciﬁc
opics; using their expertise to interpret the evidence, they com-
iled the speciﬁc chapters. The ﬁnal version of the manuscript was
ssembled using a step-wise editing process conducted via web-
ased communication. The steering and writing committees sought
dditional opinions from an external group of experts who offered
heir input on an individual basis. The proposed systems medicine
pproach for the clinico-pathological assessment of the complex
bnormalities that have an impact on NAFLD was used as a basis
or launching a large prospective cohort study supported by the
ISF.
. Pathophysiology
Obesity and insulin resistance (IR) lead to intrahepatic triglyc-
ride storage, considered the ‘ﬁrst hit’, that ultimately leads, after
 ‘second hit’ [7], to hepatocyte necrosis, inﬂammation and ﬁbro-
is (NASH). More recently, this view was challenged by a ‘multiple
its’ hypothesis, where multiple extra- and intra-hepatic signals
re implicated [8–11]. Lipotoxicity is not necessarily linked to tri-
lycerides accumulating within the liver, as some free fatty acids
FFA; palmitate and other lipotoxic intermediates) were shown to
e more hepatoxic than triglycerides [8–11]. Moreover, the liver is
argeted by signals from other tissues, including adipose tissue, the
ut and its microbiota..1. Lipid partitioning, lipotoxicity and insulin resistance
The increased ﬂux of FFA from an enlarged and insulin-resistant
dipose tissue to the liver is considered the major determinant,ge, male sex, cigarette smoking, hypertension (i.e., blood pressure ≥140/90 mmHg
glycerides ≥150 mg/dl and/or HDL-C <50 mg/dl in women <40 mg/dl in men or on
l/min/1.73 m2).
with smaller contributions from dietary fat and de novo lipogen-
esis [12–15]. In the liver, the bulk of absorbed FFA is re-esteriﬁed,
packaged into very-low density lipoproteins (VLDL) and exported
into the bloodstream as triglyceride-rich particles for supplying
peripheral tissues. If the ability of insulin to suppress VLDL secre-
tion is impaired, the result is atherogenic dyslipidaemia [13]. Liver
steatosis per se does not cause liver necro-inﬂammation, and could
even be seen as a mechanism for preventing lipotoxicity, allowing
the storage of FFA in a less harmful form [14,15]. Lipotoxic inter-
mediates and diacylglycerol (DAG) were implicated in hepatic IR,
which, in turn, directly contributes to systemic IR and worsens both
glucose and lipid metabolism [15].
2.2. Hepatic consequences of deranged metabolism
Different hepatic cell types and intracellular pathways deter-
mine the amount of damage and likelihood of progression to
advanced ﬁbrosis [16,17]. Kupffer cells play a key role in the patho-
genesis of NASH; in mice, depletion of these cells ameliorates
steatosis, inﬂammation, hepatic injury and ﬁbrosis [17]. Kupffer
cell activation is mainly dependent on danger signals from steatotic
hepatocytes and the accumulation of toxic lipids and bacterial
products, and is a critical contributor to the recruitment of mono-
cytes into the liver.
Different signalling pathways regulate intra-hepatic inﬂamma-
tion. Inﬂammasome was  indicated as a pivotal regulator of the
interactions with the gut microbiota implicated in the progres-
sion of NAFLD and obesity [16–18]. NASH is characterized by
hepatocyte apoptosis and apoptotic bodies are pro-inﬂammatory
and pro-ﬁbrogenic [19]; lipotoxic apoptosis is mediated by oxida-
tive stress, considered a ‘second hit’, causing progression to NASH
[8,20]. Autophagy is another relevant pathway for NAFLD patho-
genesis; its inhibition increases triglyceride storage, but activation
favours the progression of ﬁbrosis [21].
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.3. Adipose tissue and NASH
Adipose tissue is a critical site for the development of systemic
R and an altered pattern of adipokine secretion is pivotal for adi-
ose tissue dysfunction [22–25]. Leptin has pro-ﬁbrogenic effects
n the liver, via activation of several biological functions of hepatic
tellate and Kupffer cells [23]. Adiponectin increases insulin sensi-
ivity and has anti-inﬂammatory and anti-ﬁbrogenic effects in the
iver and in adipose tissue [22,24]. The renin–angiotensin system is
nother major modulator of IR, critical for liver inﬂammation and
brogenesis [25].
.4. Diet and gut microbiota
The gut microbiota contributes to obesity and fatty liver [26] and
he intestinal immune system is critically involved in the regula-
ion of gut microbiota and NALP3 for experimental NASH [18]. The
everity of NAFLD histology was associated with higher carbohy-
rate intake (fructose and sucrose) [27] and accumulating evidence
uggests that coffee might be protective on progression of NAFLD
nd ﬁbrosis [28].
. Diagnosis
The clinico-epidemiological features of high-risk groups play a
ajor role in guiding the physician to suspect NAFLD and NASH in
he single patient (age, sex, ethnicity, body weight and metabolic
tatus) [1–6], whereas serum transaminases do not qualify as mark-
rs of NAFLD or NASH [29]. Liver biopsy is a “gold standard” for the
iagnosis of NAFLD, even if the number of fat-containing hepato-
ytes does not correspond exactly to the quantiﬁcation obtained
y magnetic resonance proton spectroscopy (1H MRS) fat-fraction
30–46]. Its major limitation is the tissue sample size, which corre-
ponds only to 1/50,000th of the liver compared with 1/150th for
RS. Fat accumulation is spatially heterogeneous; a single biopsy
ay  not adequately represent the overall fat content of the liver
31,32]. In addition, liver biopsy is invasive and impractical in mon-
toring persons at risk of fatty liver disease.
Ultrasound is the most commonly used technique for diagno-
is [33,34], based on qualitative features, including echogenicity,
cho-texture, beam attenuation, diaphragm and vessel visibil-
ty. Fat accentuates scattering; therefore, fatty liver appears
yper-echogenic. Because there is no absolute echogenicity for
at inﬁltration, a comparison of echogenicity of the kidney is
equired. These ultrasonographic criteria have a sensitivity range
f 60–95% and speciﬁcity of 84–100%; in obese patients the sen-
itivity and speciﬁcity are reduced to 49% and 75% respectively
38]. Semi-quantitative ultrasound criteria (mild, moderate or
evere steatosis) are affected by subjective interpretation, with
oor reproducibility and a low sensitivity for mild steatosis [35].
ecently, several methods were proposed for the quantitative
ssessment of liver fat content using a combination of computer-
ssisted measures [39–43]. The computer-aided measurement of
he ultrasound hepatic/renal echo intensity ratio and the hepatic
cho intensity attenuation rate strongly correlated with liver fat
ontent according to either histology or 1H MRS  [38–43]. Therefore,
he combination of ultrasound-based quantitative methods could
e used to measure liver fat in clinical practice; however, prospec-
ive studies are needed to assess their accuracy and reproducibility.
1H MRS  techniques can measure liver fat, decomposing the
iver signal into its fat and water components; the measure is
ot inﬂuenced by ﬁbrosis or obesity and was proven to be highly
eliable [38–43]. Its limitations are mainly costs and small spa-
ial coverage with subjective positioning of the volume of interest
hat may  affect accuracy. 1H MRS  is now considered the goldDisease 48 (2016) 333–342 335
standard – replacing liver biopsy – as the non-invasive modality
for fat liver quantiﬁcation. Chemical shift imaging (CSI) acquired
routinely in liver MRI  is also used for liver fat quantiﬁcation and
showed very good correlation with hepatic fat at histology [44].
4. Rationale and methodology of a cohort study
A better understanding of the multiple risk and pathogenetic
factors of NAFLD/NASH is mandatory for new diagnostic strate-
gies, and individualized prevention and management. We  analysed
herein the major pathophysiological systems, factors and co-
factors involved in NAFLD/NASH and, using a “systems medicine”
approach, we propose new algorithms to stage and/or grade their
involvement in the individual.
4.1. Genetics
Heritability plays a major role in the progression of NAFLD
towards ﬁbrosing NASH and genome-wide association stud-
ies have identiﬁed common genetic determinants of steatosis
[45–53]. Patatin-like phosholipase-domain-containing-3 (PNPLA3)
rs738409 C>G single nucleotide polymorphism, encoding for I148M
protein variant is a major determinant [54–59]. The I148M allele
frequency explains the inter-ethnic variability of NAFLD: higher
in Hispanics (minor allele frequency [MAF] 0.49) than in Euro-
peans (MAF 0.23), and less common in Afro-Americans (MAF 0.17).
The PNPLA3-I148M variant hampers triglyceride esterase causing
reduced remodelling of lipid droplets in association with exces-
sive intake of carbohydrates or saturated fatty acids and other
genetic factors [60–63]. The association between the I148M variant
and NAFLD holds true both in adults and in adolescents [64–68];
I148M allele homozygosity predisposes to NASH and hepatic ﬁbro-
sis [56–58]. The association between the I148M variant and ﬁbrosis
is also evident in chronic viral hepatitis and genetic diseases, such
as hereditary haemochromatosis [69–71]. In addition, the I148M
variant predisposes to hepatocellular carcinoma (HCC), indepen-
dently of the aetiology of chronic liver disease, and homozygous
patients have a worse prognosis [72–76]. The TM6SF2-E167K vari-
ant was  also associated with NAFLD [53]; it favours progression to
NASH and ﬁbrosis by impairing the secretion of very low density
lipoproteins in hepatocytes, but protecting from atherosclerosis
[59,77]. Therefore, both PNPLA3-I148M and TM6SF2E167K may
be useful in identifying NAFLD patients at a higher risk of hepatic
than cardiovascular complications and the PNPLA3-based categori-
sation of NAFLD may  have therapeutic implications. Preliminary
data suggest that I148M-homozygous subjects might beneﬁt from
weight loss after a short-term low-carbohydrate diet [68,78]; how-
ever, disease progression is modulated by multiple environmental
and genetic factors [48,79–82]. Thus, PNPLA3 I148M and TM6SF2
variants plus/minus a family history for cirrhosis and/or HCC and
ethnicity can be used to stratify patients at risk in clinical practice
(Table 2).
4.2. Age and gender
4.2.1. Childhood
In children, in whom alcohol abuse, drug consumption and
co-morbidities are much less important than in adults, NAFLD is
generally considered to be of primary origin [83]. Genetic back-
ground, epigenetic programming, intra-uterine environment and
post-natal nutrition are major risk factors and single nucleotide
polymorphisms (SNPs) may  identify children who  are at a higher
risk of NAFLD [55,56,60,63,65]. In fact, the PNLA3 rs738409 C>G
SNP polymorphism was associated with higher risks of fatty liver,
NASH and ﬁbrosis [64,67]. Intrauterine malnutrition causes a foetal
336 S. Petta et al. / Digestive and Liver Disease 48 (2016) 333–342
Table 2
Genetic factors score.
Risk score
Ethnicity
Afro-American 0
Asiatic or European 0.5
Hispanic 1
Family history for NAFLD/NASH
Negative 0
Present in one parent 1
In more than one sibling 1.5
In both parents 2
PNPLA3 I148M
Normal 0
Heterozygous 0.5
Homozygous 1
TM6SF2 E167K
Absent 0
Present 1
The overall score of genetic factors impact ranges from 0 to 5 resulting form the sum
of  the values of 3 different categories of genetic factors.
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Table 3
Hypothesis of a sex-related score for fatty liver disease.
Females Males
(a) Effect of age
<12 years 0 0
>12  < 50 years 1 2
>50  years 3 3
Type Females Males Clinical features
(b) Added effect of body weight and fat distribution
A  0 0 Normal weight, female or male, without either
gluteo-femoral or visceral fat accumulation pattern
B  1 3 Female overweight but without gluteo-femoral
and or visceral fat accumulation or male
overweight without visceral accumulation
C  2 4 Female overweight with gluteo-femoral and orbbreviations:  NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steato-
epatitis; PNPLA3 I148M, patatin-like phosholipase-domain gene I148M variant;
M6SF2 E167K, trans-membrane 6 superfamily member 2 gene E167K variant.
daptive response with a consequent permanent reprogramm-
ng of tissue structures and functions [84–86]. NASH and MetS
ere reported to be higher in children with intrauterine growth
etardation, who  were overfed after birth, possibly because of dis-
ordance between intrauterine and extrauterine environments,
hereas breastfeeding seems to protect from NASH [87,88]. These
tudies suggest that prenatal and postnatal periods are critical
or metabolic programming [89,90]. Also, physical inactivity and
xcessive caloric intake are responsible for the “obese and metabol-
cally dysfunctional” phenotype; diets rich in sugar (soft drinks
ith fructose-based corn syrup), salt and saturated fats and poor
n micronutrients are associated with obesity and NAFLD [91,92].
.2.2. Gender
The prevalence of NAFLD is higher in men  with an “inverted
 shaped curve”: it increases from young to middle-aged indi-
iduals and declines in the elderly [93]. The “protective” female
ardio-metabolic phenotype, present in Caucasians and Asiatics,
ut not in Hispanics and Blacks, disappears with the menopause
94–98]. Accumulated experimental and clinical evidence sug-
ests that estrogens might exert protective effects on the interplay
mong brain, endocrine and digestive systems and consequently
orbidity and mortality [99–104]. However, the impact of oestro-
en replacement in post-menopausal women with NAFLD is still
ebated [105]. Thus, gender and age-related hormonal changes
hould be considered for the re-deﬁnition of clinical phenotypes,
oth in a new “patient based” approach and in preventive edu-
ational programmes. On this basis, a tentative quali–quantitative
core for grading the impact of gender on liver steatosis in rela-
ion to age, weight and fat distribution may  be applied to stratify
ndividuals with fatty liver disease (Tables 2 and 3).
.3. Nutrition
The epidemiology of nutrition is a paradox: on the one hand,
besity has doubled in the last 30 years, reaching about one-third of
he global population; on the other hand, malnutrition affects about
 billion people worldwide. Fatty liver occurs in the most severe
orms of protein calorie starvation, such as kwashiorkor anorexia,
ulimia, cachexia, massive (rapid) weight loss, and uncontrolled
nﬂammatory bowel diseases [106]. However, NASH and ﬁbrosis
re highly unusual in these conditions. A typical American dietvisceral fat accumulation or male with visceral fat
accumulation, independently of body weight
(100 g of fat daily) supplies the liver with ∼20 g of fat, equiva-
lent to one-half of the total triglyceride (TG) content of an average
liver, while the ﬂux of FFA through the bloodstream amounts to
∼100 g/day, with 20% being extracted by the liver. Thus, the daily
input of TG from the diet (∼20 g/day) and FFA from adipose tis-
sue (∼20 g/day) approximates the entire TG content of the liver
[107]. Under conditions of an acute intake–expenditure imbal-
ance, metabolic tissues store excess nutrients for future use. With a
chronic imbalance, the physiological storage capacity is exceeded,
activating cellular stress signalling pathways that attempt to stem
further nutrient inﬂux by inhibiting insulin signalling and pro-
moting inﬂammation. In obesity-induced metabolic diseases, the
continued nutrient imbalance drives this process forward, leading
to chronic inﬂammation and IR and, ultimately, to type 2 diabetes,
cardiovascular disease (CVD) and other overtly pathological con-
sequences. It has been reported that when IR is induced by excess
nutrient intake, 59% of hepatic fat is derived from circulating FFA,
with lesser contributions from de novo lipogenesis (26%) and diet
(15%) [12]. Thus, overfeeding induces subcutaneous and visceral
obesity; the latter directs an increased ﬂux of FFA directly to the
liver, thereby making a greater contribution to hepatic steatosis.
Few studies have evaluated the role of food quantity and quality
on NAFLD development and clinical outcomes [108]. The Mediter-
ranean diet is associated with an improvement in health status, as
indicated by a signiﬁcant reduction in overall mortality (9%), mor-
tality from CVD (9%), mortality from cancer (6%) and incidence of
Parkinson’s disease and Alzheimer’s disease (13%) [109,110]. Con-
cerning NAFLD and NASH, there are currently a few studies with
low numbers of patients. Dietary habits, in particular saturated fat,
may  promote NASH by modulating hepatic triglyceride accumu-
lation and antioxidant activity, and indirectly by affecting insulin
sensitivity and postprandial triglyceride metabolism [111].
The American Heart Association recommends that added sug-
ars should represent less than 5% of total calories (corresponding
to 2.5% of calories from fructose), in spite of this the percent-
age of total energy from added sugars is still approximately
14–15% [112,113]. Substantial relationships have been demon-
strated between increased fructose consumption and obesity,
dyslipidemia and IR [114]. Compared with glucose, fructose
enhances de novo lipogenesis, promotes postprandial hypertriglyc-
eridaemia, induces hepatic and extrahepatic IR, reduces satiety and
increases visceral adiposity. The mechanism behind the fructose-
induced expansion of ectopic fat is still under intense investigation,
but it is hypothesized that fructose might be a strong inducer of
de novo lipogenesis, which only produces saturated fatty acids.
Fructose consumption may  induce hepatic lipid accumulation by
activating lipogenic gene expression. Another explanation might
be the direct ﬂow of fructose carbon into the glycolytic pathway,
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ypassing a key regulatory enzyme of glycolysis, phosphofructoki-
ase. Through this route, a higher proportion of the carbon from
ngested fructose, compared with glucose, is incorporated into tri-
lycerides. Abdelmalek et al. studied the histological severity of
AFLD according to daily fructose intake in a large cohort of adults:
lthough the steatosis grade was lower in those with increased
ructose intake, the degree of ﬁbrosis was higher [115]. The daily
ntake of industrial, not fruit, fructose is a risk factor for severe liver
brosis, at least in patients with chronic hepatitis C (CHC) [116].
.3.1. Alcohol intake in NAFLD
There is a great deal of uncertainty regarding the deﬁnition of the
hreshold of alcohol consumption and the duration of abstinence
eeded to rule out NAFLD [117]. A light-to-moderate alcohol con-
umption (deﬁned as less than 20 g per day) was associated with a
ecreased prevalence of NASH and a lesser degree of hepatic ﬁbro-
is in a large survey of patients selected from a well-characterized
opulation with biopsy-proven NAFLD, suggesting that light-to-
oderate alcohol consumption might have a protective effect
n NAFLD progression [118]. Such ﬁndings, however, should not
ncourage physicians to recommend alcohol drinking to teeto-
allers with NAFLD.
.4. Metabolic and endocrine systems
.4.1. Insulin resistance
IR is deﬁned as a decreased sensitivity or responsiveness to
he actions of insulin that promote glucose disposal. It plays a
ajor role in type 2 diabetes, and is closely associated with
he cluster of metabolic abnormalities that deﬁne MetS [119].
R is a characteristic feature of NAFLD, even in non-obese,
on-diabetic subjects [120], and affects both lipid and glucose
etabolism in target organs (liver, skeletal muscle, adipose tissue
nd myocardial muscle). As IR is the hallmark of obesity and several
etabolic complications, including NAFLD, quantifying insulin sen-
itivity/resistance in humans is of great importance. Several direct
nd indirect methods are currently employed, some of them rely-
ng on steady-state analysis of glucose and insulin concentrations,
thers – such as the gold standard hyperinsulinaemic–euglycaemic
lamp – on dynamic testing. Simple surrogates, such as the homeo-
tasis model assessment of IR (HOMA-IR) and the quantitative
nsulin sensitivity check index (QUICKI) are those most extensively
sed. Both indices are derived from fasting plasma insulin and
lucose concentrations. HOMA-IR is calculated as {[fasting insulin
U/ml)] × [fasting glucose (mg/dl)]}/22.5 [121]. HOMA-IR ≥ 3 gen-
rally deﬁnes a condition of IR, but the coefﬁcient of variation
f HOMA-IR varies considerably depending upon the number of
amples obtained and the insulin assay used [122]. QUICKI can be
alculated from a mathematical transformation of HOMA [123].
lthough HOMA-IR and QUICKI are suited for use in large epidemi-
logical or clinical research studies, their speciﬁcity in evaluating
nsulin sensitivity in individual patients is low.
.4.2. Metabolic syndrome (MetS) and its clinical features
The MetS is a cluster of interrelated metabolic conditions that
xponentially increase the risk of developing CVD, type 2 diabetes
nd NAFLD (Table 1).
The association between NAFLD and the features of MetS is well
stablished. Prevalence of the MetS in NAFLD varies from 18% in
ormal-weight individuals to 67% in obese subjects [124]. In type diabetes, NAFLD can be diagnosed by ultrasound scan in 69% of
ases [125] and 87% of the patients with fatty inﬁltration who con-
ented to biopsy have histological conﬁrmation of NAFLD [126]. The
revalence of NAFLD in individuals with dyslipidaemia is estimated
o be 50% [127].Disease 48 (2016) 333–342 337
In this complex interplay, obesity, which has reached epidemic
proportions worldwide, is the most common and well-documented
risk factor for NAFLD, visceral obesity playing a prominent role
in the development of MetS features, including NAFLD [128]. A
Chinese study enrolling 5562 subjects who  were NAFLD free at
baseline, reported that MetS was  independently associated with
the presence and development of NAFLD during a 5-year follow-
up [129]. Along the same lines, a study in the USA reported that
“lean NASH” was independently associated with Hispanic ethnicity,
younger age and some features of MetS, such as hypertension [130].
Another study enrolling 29,994 adults reported that non-obese
patients with NAFLD had a higher prevalence of MetS features than
obese patients without NAFLD, especially among women [131]. A
large Korean occupational cohort study, involving 2589 subjects
who were NAFLD free at baseline, and who  were re-examined
after a mean of 4.4 years, reported that elevated triglycerides and
fasting glucose levels and enlarged waist circumference were inde-
pendently associated with incident NAFLD [132]. Furthermore, the
same metabolic risk factors appear to be associated with its pro-
gression to NASH. In 109 NASH patients who underwent a second
liver biopsy at least 3 years after the ﬁrst, progression of liver ﬁbro-
sis was  found in approximately 30% of patients and was associated
with increased waist circumference and BMI  [133]. Severe liver
damage was associated with decreased insulin sensitivity mea-
sured by the oral glucose tolerance test-derived oral glucose insulin
sensitivity [134] and MetS [135]. Obesity and type 2 diabetes are
also implicated in the development of HCC, even in the absence of
severe ﬁbrosis [136]. Of note, the relationship between NAFLD and
MetS is bidirectional. Liver fat content, as detected by 1H MRS, is
about 4-fold higher in those with than in those without MetS [107].
The risk of CVD mortality and morbidity greatly exceeds the risk of
liver-related mortality; thus, NAFLD is not merely the hepatic man-
ifestation of MetS, but rather a systemic pathogenic component (or
precursor) of this syndrome [137,138]. Accordingly, we  propose a
score combining visceral obesity with one or more features of MetS
to stratify NAFLD individuals (Tables 2–4).
4.4.3. Thyroid dysfunction
A consistent line of research has associated thyroid dysfunction
with NAFLD [139–141]. A German study reported that low free thy-
roxine levels were associated with ultrasound-detected steatosis
in 3661 participants with no history of thyroid or liver diseases
[142]. Another study of 4648 health-check subjects (2324 subjects
with hypothyroidism vs age- and sex-matched controls) reported
that subclinical hypothyroidism was  related to NAFLD in a dose-
dependent manner [143].
4.5. Cardiovascular system
In the last decade, it became evident that the clinical burden
of NAFLD is not restricted to liver-related morbidity or mortality,
and that the majority of deaths among these patients are related to
malignancy, coronary heart disease (CHD) and other cardiovascular
complications [6]. The spectrum of cardiovascular complications
associated with NAFLD spans from premature atherosclerosis to
aortic valve sclerosis and left ventricular dysfunction/hypertrophy
leading to congestive heart failure and cardiac arrhythmias (mainly
atrial ﬁbrillation) [138,144–147]. Growing evidence indicates that
NAFLD may  play a role in the development and progression
of cardiovascular complications, not only through MetS, but
also through multiple pathophysiological derangements, including
chronic inﬂammation, hypercoagulation, chronic kidney disease,
hyperuricaemia, hypovitaminosis D, hypoadiponectinaemia, and
increased fetuin-A levels [138,146,147]. NAFLD exacerbates IR,
causes atherogenic dyslipidaemia, and releases pro-inﬂammatory,
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Table 4
Cardiovascular risk.
Score Degree of impairment of cardiovascular system Patients CVD risk factors and/or Framingham risk scorea
0 Minimal Asymptomaticb Either <3 traditional CVD risk factorsc or a low/intermediate Framingham
risk  score (i.e. a 10-year CHD risk <15%)
1  Intermediate Asymptomaticb Either a high Framingham risk score (i.e. a 10-year CHD risk >15%) or ≥3
traditional CVD risk factorsc
2 Severe In secondary prevention of CVD or at very high CVD risk (e.g., angina, myocardial infarction,
coronary revascularization), stroke or other clinical CVD complications such as peripheral artery
disease, abdominal aortic aneurysm or carotid artery stenosis >60% or established diabetes
a The 10-year risk of having a CVD can be estimated by the Framingham risk score equation inserting major CVD risk factors (i.e., age, sex, total cholesterol, HDL-cholesterol,
smoking history, systolic blood pressure and current use of anti-hypertensive drugs) of the individual patient in the NIH web  site: http://cvdrisk.nhlbi.nih.gov/.
b All patients included in either score 0 or score 1 are in primary prevention of CVD.
c Traditional CVD risk factors considered are as follows: family history of premature CVD, age, male sex, cigarette smoking, hypertension (i.e., blood pressure ≥140/90 mmHg
o .e., triglycerides ≥150 mg/dl and/or HDL-C <50 mg/dl in women <40 mg/dl in men or on
t  <60 ml/min/1.73 m2).
C h density lipoprotein cholesterol; CKD, chronic kidney disease.
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Table 5
Grading of the impact of chronic infections and/or immune disorders on fatty liver.
Grade Infections and/or immune disorders
0 Absence of clinical and pathological signs of immune disorders,
circulating autoantibodies and chronic HBV or HCV infections
1  One of the following features: clinic-pathological signs of immune
disorders or circulating auto-antibodies and chronic HBV or HCV
infection without chronic active hepatitis (inactive HBsAg carrier
or  anti-HCV positive but HCV-RNA negative)
2  Both clinical or pathological signs of immune disorders or
circulating auto-antibodies and chronic HBV or HCV infection
without chronic hepatitis (inactive HBsAg carrier or anti-HCV
positive but HCV-RNA negative)
3  Chronic hepatitis Br  on treatment), LDL-C ≥130 mg/dl (or on treatment), atherogenic dyslipidemia (i
reatment), obesity (BMI ≥30 kg/m2) and CKD (estimated glomerular ﬁltration rate
VD, cardiovascular disease; LDL-C, low density lipoprotein cholesterol; HDL-C, hig
ro-coagulant, pro-oxidant and pro-ﬁbrogenic mediators of cardio-
ascular pathophysiology [138,144–147].
Based on this evidence, scientiﬁc societies have suggested an
ssessment of the overall CVD risk in patients with NAFLD [1,148];
owever, how such an assessment should be conducted is still
oorly deﬁned [146] and in general it follows the guidelines for
he CVD risk of the general adult population [146,117,149]. Pre-
iminary evidence suggests that the Framingham risk score might
ccurately predict the higher 10-year CHD risk in patients in the
SA with NAFLD and identify patients expected to beneﬁt from
arly interventions to prevent CHD events [149,150]. However, the
ccuracy of the Framingham risk score needs to be further validated
n European patients with NAFLD, where this equation may  over-
stimate the CHD risk compared with populations of Anglo-Saxon
ncestry. Furthermore, future studies in larger cohorts of NAFLD
atients with different ethnicities are needed to validate the Fra-
ingham or other risk score systems for predicting the global CVD
isk, given that subclinical inﬂammation, IR and hypertriglyceri-
aemia are not considered in any of the available risk score systems.
n Table 4 we propose a grading scale for global CVD risk in NAFLD
ased on available evidence and guidelines.
.6. Immune disorders, chronic viral infections, and gallstone
isease
.6.1. Immune disorders
Both innate and adaptive immune response play a pivotal role
n the pathogenesis and progression of NAFLD [9,151,152]. Exper-
mental observations match clinical evidence on the association
etween immune disorders and the presence/severity of NAFLD
153,154]. Circulating autoantibodies are frequent in NAFLD in
he absence of autoimmune hepatitis and associated with more
dvanced liver disease at histology [155]. Serum IgA levels are sig-
iﬁcantly associated with NASH and more advanced liver ﬁbrosis
n NAFLD [153,154]. An intriguing link between immune disorders
nd NAFLD is suggested by the prevalence of fatty liver in rheuma-
ological disorders [156], primary biliary cirrhosis [157–159],
oeliac and inﬂammatory bowel diseases (IBD) [160–163]. NAFLD
s the third most common IBD-associated liver disease independent
f classical risk factors such as obesity, IR or drug toxicity [161,162].
.6.2. Chronic viral infections
Fatty liver is common in patients with CHC, with prevalence
anging from 40 to 80%, higher than in chronic liver diseases of dif-
erent aetiology [164,165]. The pathogenesis of steatosis in CHC is
ultifactorial, involving both host and viral factors. A direct steato-
enic effect was shown for hepatitis C virus (HCV) genotype 3
166–170], where steatosis is more frequent and severe accord-
ng to viral load [167,168] and disappears after viral eradication4  Chronic hepatitis C
HBV, hepatitis B virus; HCV, hepatitis C virus; HBsAg, hepatitis B surface antigen.
[171]. Conversely, a combined viral and metabolic steatosis occurs
in non-3 HCV genotype infections and correlates with age and IR
[170]. Nevertheless, HCV genotype 1 can induce IR [171–175]. Inter-
esting ﬁndings support the interplay between the host’s genetics
and fatty liver in HCV-infected individuals: the PNPLA3 l148M vari-
ant [176] is associated with steatosis, whereas the IL28B rs868 CC
genotype is associated with a sustained response to peginterferon
and ribavirin and lower prevalence of IR and steatosis [177]. Fur-
thermore, steatosis has a relevant impact on the clinical history of
HCV infection (liver disease progression and HCC) [170,178–185].
The association between chronic hepatitis B virus (HBV) infection
and steatosis is less evident than in CHC; the prevalence of fatty
liver is extremely variable (5–70%) [186–192]. Nevertheless, steato-
sis is more frequent in chronic hepatitis B (CHB) patients than in
the general population in Western and Asian countries without the
impact of ethnicity or viral genotypes [190–192]. In most studies of
CHB patients steatosis was not associated with ﬁbrosis; this raises
the question whether NAFLD in HBsAg carriers might be linked
to metabolic factors indirectly inﬂuenced by HBV. As in chronic
HCV infection, the pathogenesis of steatosis is related to metabolic
factors such as obesity and IR [187–189] and genetic background
(PNPLA3 I148M variant) [70], but at variance with HCV a direct
steatogenic impact of HBV has been reported in a few experimental
studies [191–195]. Whatever the underlying mechanisms, steatosis
in both CHB and CHC represents an important co-factor affecting
the outcome of liver disease [192]. Thus, we  proposed a scale for
grading the combined impact of immune disorders and viral infec-
tions in NAFLD patients (Table 5).4.6.3. Gallstones or cholecystectomy
Studies of the association between NAFLD and gallstones pro-
vided conﬂicting results. In a large study NAFLD was  associated
with cholecystectomy, but not with gallstones, suggesting that
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holecystectomy might be a potential risk factor [196]. Another
tudy found a high prevalence of gallstones in NAFLD patients with
lucose intolerance/diabetes and advanced liver disease [197].
. Future perspectives
With this approach, it is possible to characterize different
AFLD/NASH phenotypes within the deﬁnition of the general
etabolic syndrome. Based on this premise we aim to launch a
arge observational cohort study supported by AISF and the Foun-
ation for Research in Hepatology (FIRE). The goal is to study the
linical comorbidities and hepatic and extrahepatic outcomes asso-
iated with subsets of patients with NAFLD/NASH, to increase the
nderstanding of the complex interplay among different physio-
ogical systems. A prospective cohort of consecutive asymptomatic
ndividuals with fatty liver will be recruited in clinical centres dis-
ributed throughout Italy and followed up for at least ﬁve years.
ovel statistical models such as non-linear and integrative epi-
emiological approaches [198], accounting for the patterns of
nterconnections between parameters affecting disease risk and
heir correlations, will be used to better understand the mecha-
isms involved. With this integrated approach we hope to identify
ew diagnostic and prognostic biomarkers and new targets for pre-
ention and treatment.
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